Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383771 | 0.87 | HRH3 (0.63) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL4387966 | 0.86 | HRH3 (0.72) | HRH3SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL4389440 | 0.85 | HRH3 (0.58) | HRH3HRH1 | |
| SCHEMBL4384077 | 0.85 | HRH3 (0.56) | HRH3SMN1; SMN2ALDH1A1HRH1 | |
| SCHEMBL4384094 | 0.85 | HRH3 (0.56) | HRH3SMN1; SMN2ALDH1A1HSD17B10DRD2 | |
| SCHEMBL4396189 | 0.84 | HRH3 (0.73) | HRH3SMN1; SMN2USP2TSHRALDH1A1 | |
| SCHEMBL4396186 | 0.84 | HRH3 (0.73) | HRH3SMN1; SMN2USP2TSHRALDH1A1 | |
| SCHEMBL4383854 | 0.84 | HRH3 (0.61) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL4389078 | 0.83 | HRH3 (0.76) | HRH3SMN1; SMN2USP2TSHRALDH1A1 | |
| SCHEMBL4383193 | 0.83 | HRH3 (0.60) | HRH3SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | ARG1, PRMT5, PRMT1 | HRH3 452/4885SMN1; SMN2 3979/4885USP2 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.